New Drugs & Clinical Trials Rules, 2019

New Drugs and Clinical Trials Rules, 2019

1. Definition, statutory basis & why the Rules exist

• The New Drugs and Clinical Trials Rules, 2019 (NDCT Rules 2019) are subordinate legislation notified under the Drugs and Cosmetics Act, 1940 (the parent Act) and made by the Central Government; "Act" throughout the Rules means the D&C Act 1940 (NDCT 2019 r.2(1)(b)).
• They are a standalone, consolidated code that carved the regulation of clinical trials, BA/BE studies, new-drug approval and Ethics Committees out of the older Drugs and Cosmetics Rules, 1945 — replacing the regime that lived in Schedule Y of the 1945 Rules with a dedicated, modern instrument (NDCT 2019 r.1; KDT 8e Ch.5, p.88 still describes the pre-2019 position: "requirements and regulations for the conduct of clinical trials on a new drug in India have been laid down in the Schedule Y of the Drugs and Cosmetics Rules").
• Commencement: the Rules came into force on the date of their publication in the Official Gazette (19 March 2019), except Chapter IV (Ethics Committee for Biomedical & Health Research), which came into force 180 days later (NDCT 2019 r.1(2)).
• Applicability (r.1(3)): they apply to all new drugs, investigational new drugs for human use, clinical trials, bioequivalence studies, bioavailability studies, and Ethics Committees in India.
• Amendment: materially amended by G.S.R. 21(E) dated 18-01-2022, which (among other things) refined definitions (e.g. "Designated Registration Authority", "BA/BE centre clinical+analytical part") and Chapter IV registration mechanics (NDCT 2019, amendment marginalia at r.2(1)(la), r.2(1)(g)).
• Driving rationale (exam-relevant "need" framing): the Rules were a regulatory response to a decade of controversy over unethical trials, inadequate compensation for trial injury/death, and opaque/slow approval timelines in India; they were designed to make the system predictable (defined timelines + deemed/automatic approval), accountable (mandatory compensation, EC registration), and globally credible while incentivising drugs discovered/developed in India (NDCT 2019 r.22, r.23, r.39, r.8; conceptual parallel — G&G 14e Ch.1, pp.13–14, on how the US FDA framework evolved after the elixir sulfanilamide and thalidomide tragedies).